• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    A

    Association of Community Cancer Centers

    EST. 1974
    122论文总数
    463引用总数

    论文量&引用量时间轴

    机构学者

    论文(122)

    年份
    起
    –
    止
    排序
    1PP01.112: Improving Lung Cancer Screening Access in Rural Appalachia: Outcomes from a Regional Quality Initiative
    Laura D'Onofrio, Michael Gieske, Dina Avery, Nicole A. Colwell, Kim Demirhan
    2026JOURNAL OF THORACIC ONCOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    2Baseline Findings to Inform Quality Improvement Opportunities in Low-Risk Myelodysplastic Syndromes
    Fiona He, Emily Stickney, Nicholas Rohde, Colton Zwart, Rashida Taher, Vivian Dondlinger, Molly Kisiel, Nicole Colwell, Kimberly Demirhan

    Abstract Background: Low-risk myelodysplastic syndromes (MDS) are heterogeneous hematologic disorders often presenting with anemia and fatigue in older adults with comorbidities. Optimal management requires comprehensive diagnostic evaluation and multidisciplinary care. Real-world practice often reveals variability in testing, treatment initiation, and monitoring. To identify existing gaps in care and potential opportunities for improvement, the Association of Cancer Care Centers worked with 3 cancer centers in Minnesota, Michigan, and Rhode Island on a quality improvement (QI) project focused on low-risk MDS. Methods: Sites retrospectively reviewed records of patients with low-risk MDS actively receiving treatment. Data points included:Symptoms documented at the time of diagnosisCytogenetic testing and molecular testing rates,Serum erythropoietin (EPO) level checked prior to receiving an erythropoiesis-stimulating agent (ESA)Ferritin monitoring in transfusion-dependent patients. Sites reviewed these findings in a multidisciplinary QI workshop and identified targeted interventions. Results: Baseline data included 56 patients diagnosed with low-risk MDS and actively receiving treatment. The data revealed the following:46.4% reported symptoms at the time of diagnosis; 37.5% had no symptoms; 16.1% had no clear documentation about symptoms.84.2% received cytogenetic testing at diagnosis. 50% received molecular testing at diagnosis.Among 30 patients treated with ESAs for anemia, 66.7% had a baseline serum EPO.Among 19 patients who were transfusion-dependent, 84.2% had a recent ferritin level.12.5% were treated with lenalidomide. 17.9% were treated with luspatercept. QI interventions recommended standardizing diagnostic workflows to include molecular testing for all patients diagnosed with MDS, updating treatment plans to ensure baseline erythropoietin (EPO) levels are ordered prior to initiating ESA therapy, implementing audit and feedback processes to identify patients who may require ESA dose adjustments or are not responding to therapy, and assessing patients for iron overload to support timely chelation therapy discussions. Conclusions: Baseline data from this multicenter QI initiative reveals variability in key diagnostic and treatment-related processes for low-risk MDS, with gaps noted in molecular testing, ESA workup, and iron overload monitoring. These findings highlight actionable targets for standardizing care and aligning with best practices. While post-intervention outcomes are pending, these results may guide other centers in identifying and addressing similar gaps to advance patient-centered care in low-risk MDS.

    2025BLOOD(2025)
    引用
    AI阅读
    加入学术空间
    32025 Trending Now in Cancer Care: Part 2
    Monique J. Marino
    2025Oncology Issues(2025)
    引用
    AI阅读
    加入学术空间
    4Enhancing Diversity in Oncology Trials: Key Strategies from the ACORI Community Oncology Inclusive Clinical Trial Design Summit.
    Kimberly Demirhan, Shaalan Beg, Al B. Benson III, Lora Black, Molly Kisiel, Michele M. Lacy, Jane Myles,Sumanta Kumar Pal,Elana Plotkin, Lawrence David Wagman,Latha Shivakumar

    e23027 Background: Oncology clinical trials often lack ethnic and regional diversity , limiting the generalizability of findings across real-world patient populations. The Association of Cancer Care Centers (ACCC) Community Oncology Research Institute (ACORI) hosted the ACORI Community Oncology Inclusive Clinical Trial Design Summit on October 29–30, 2024 to convene multidisciplinary stakeholders to identify and address barriers to participation among underrepresented groups in clinical trials in the community settings. Methods: The summit featured didactic sessions, case-based presentations, and moderated interactive discussions with 76 participants, including 24 cancer center practitioners and researchers, 17 professional and patient advocacy organizations, industry representatives, and leaders from the FDA, NCORP, and the National Cancer Institute. The summit focused on identifying actionable solutions to expand access to clinical trials by enhancing clinical trial design, employing innovative operational delivery of trial opportunities, and building consensus on effective strategies around engagement, recruitment, and retention of participants and communities. Results: Discussions yielded the following recommendations to increase trial diversity: Strengthening the clinical trial workforce: Expand APP and clinical pharmacist roles as principal investigators through education and advocacy and strengthen training pathways for trial navigators/coordinators. Optimizing trial design and infrastructure for diverse populations: Broaden eligibility criteria, simplify protocols, and incorporate patient-friendly tools like e-consent and multilingual resources. Fostering community engagement: Build trust through local partnerships, establish patient education programs, and address systemic biases in trial recruitment. Advancing Decentralized Clinical Trials (DCTs): Advocate for flexible regulatory frameworks, educate practitioners through a DCT implementation playbook, and utilize community-based healthcare infrastructure. Leveraging AI and digital tools for trial efficiency: Apply AI for patient matching, protocol simplification, and remote monitoring, while improving transparency and interoperability with EHRs. Conclusions: Inclusive trial design and delivery of trial opportunities are essential to achieving equitable cancer care. Addressing systemic barriers and adopting innovative approaches can enhance diversity and improve the generalizability of clinical research. Through ACORI, ACCC will continue to foster collaboration among stakeholders. This remains critical to ensuring sustainable progress in community oncology research.

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)
    引用
    AI阅读
    加入学术空间
    5Early Findings from a National Quality Improvement (QI) Program to Address Disparities in Bladder Cancer (BLCA) Care.
    Ali Raza Khaki, Fionna Sun,Patrick J. Hensley,Mary Dunn, Rebecca Peebles,Stephanie Chisolm, Karen Johnson, Manish A. Vira, Bradley Curtis Carthon,Allison Harvey,Christina Mangir, Caroline Offit,

    697 Background: Rates of guideline-concordant treatment for BLCA remain <50%, driven by access and care delivery barriers. The Association of Cancer Care Centers (ACCC) designed a 6-month QI program to identify and implement site-specific strategies to support equitable care delivery at cancer programs. We aim to characterize findings from participating sites’ pre-implementation assessments as well as initial directions for QI. Methods: The ACCC QI program was conducted with cancer programs between November 2023 – November 2024, guided by an advisory committee, patient advocacy partners, and multidisciplinary faculty. Each program completed a pre-assessment to characterize organizational resources, catchment population demographics, patient volume, sentiment regarding organizational culture, practice patterns and identified barriers. Open-ended questions and those regarding sentiment used a 5-point Likert scale. During each in-person workshop, participants discussed barriers and prioritized interventions using an impact-feasibility matrix. Descriptive summary data are presented. Results: Three programs (one in California, North Carolina and Kentucky) were selected; one in an urban setting and two suburban; two NCI-designated and one Comprehensive Community Cancer program. Annual case volumes ranged from 103-1439, with 167-220 new diagnoses; >50% of cases were non-muscle invasive at each site and male-predominant (up to 30% female), with variable patient diversity (up to 50% Asian and 15% Black). Insurance coverage varied across programs: 52-80% Medicare, 17-29% Private, 0-3% uninsured. All programs agreed/strongly agreed leadership, staff and multidisciplinary team members were committed to improving equitable care, but only 1 program had processes to regularly assess disparities and 1 felt they had adequate training or culturally appropriate educational materials. Program-specific barriers to care included limitations around transportation support, limited care coordination, few community practitioners providing specialized care, and limited awareness of available resources. Based on impact and feasibility ratings, intervention targets included assessing and aligning care coordination preferences, mapping supportive care resources and addressing gaps, and tailoring educational materials to patient populations. Conclusions: Our study demonstrates a strong recognition by health systems of disparities affecting BLCA care, shows the feasibility of developing a QI program focused on addressing disparities in diverse practice settings and highlights the importance of systems-level support. Implementing mitigation strategies require program-specific understanding of barriers to provide equitable care. Health systems level strategies require a community-based approach to address barriers and deliver equitable care tailored to the needs of communities served.

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 122 篇论文

    合作机构(100)

    西北大学合作论文 9
    孟菲斯大学合作论文 6
    Sanford Health合作论文 6
    西奈山伊坎医学院合作论文 5
    希望之城国家医疗中心合作论文 5
    俄亥俄州立大学合作论文 5
    宾夕法尼亚大学合作论文 4
    纪念斯隆凯特琳癌症中心合作论文 4
    Southern Ohio Medical Center合作论文 4
    加州大学旧金山分校合作论文 4

    机构统计